Figure 1.
![Treatment with eltanexor leads to alterations in apoptotic proteins, and combination with venetoclax synergizes to inhibit growth of AML cells in vitro. Western blot analysis of MV-4-11 and MOLM-13 cells after 24 hours of treatment with dimethyl sulfoxide (DMSO [D]) or a dose titration of eltanexor (ELTA) to determine protein levels of XPO1, p53, MCL1, and cleaved caspase 3. Actin was used as a loading control. Vertical line indicates different exposures because of varying levels of endogenous XPO1.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/4/3/10.1182_bloodadvances.2019000359/2/advancesadv2019000359f1.png?Expires=1720305402&Signature=NnN80ylNHSBnpeqSviSv2OVB0fhJrB-7WtaOZ9HtSgITYfCnwT6hh9F52KNb9QaWjcB6BK1~dyljJg0sozk4YGotmYj43Q32Dc3AUjTbxSuBXigzHk1MLoKCFGjnajJgs3K~KHtuSHEZJE~fiPSKAGZ6l1XqLGlMBeoM5TBdSMzDVp57RZkmaSnh1Xr-gyQeHuLerDGM70fi-YOCvZJXRkpSgDyFeCVCAzt-HL0OCrpqQHLTIYh5yODCDO9TPURB11r8Mypi-1GJfoTtI1ungSdqHDcVzWJPH6V9Wk84E4~atdyY1mHbk31Qhydef6C6QEB6DO3S-DuV18o8pvIjTw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Treatment with eltanexor leads to alterations in apoptotic proteins, and combination with venetoclax synergizes to inhibit growth of AML cells in vitro. Western blot analysis of MV-4-11 and MOLM-13 cells after 24 hours of treatment with dimethyl sulfoxide (DMSO [D]) or a dose titration of eltanexor (ELTA) to determine protein levels of XPO1, p53, MCL1, and cleaved caspase 3. Actin was used as a loading control. Vertical line indicates different exposures because of varying levels of endogenous XPO1.